|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) is a <u>ser</u>ine <u>p</u>rotease <u>in</u>hibitor (serpin) implicated in numerous pathological processes, including coronary heart disease, arterial and venous thrombosis, and chronic fibrotic diseases.
|
30510136 |
2019 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) has been shown to be an independent risk factor for coronary artery disease.
|
9812921 |
1998 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the potential role of plasminogen activator inhibitor-1 (PAI-1) in the development of coronary artery disease is strongly supported by its biological characteristics, results of clinical studies remain controversial.
|
14629464 |
2003 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using our method, we are able to detect GE interaction of SERPINE1 and body mass index (BMI) on CHD, which has not been reported.
|
21241273 |
2011 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated PAI-1 antigen levels have been identified as a potential biomarker for coronary artery disease and metabolic syndrome while being modulated by a number of atherosclerotic risk factors.
|
29494856 |
2018 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Familial high PAI levels with concurrent hypofibrinolysis co-segregated with familial combined hyperlipidemia, both being independent risk factors for premature coronary heart disease.
|
8191398 |
1994 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans.
|
10997795 |
2000 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease.
|
11457467 |
2001 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined analyses of studies of the PAI-1 [-675] 4G variant yielded a per-allele relative risk for coronary disease of 1.06 (1.02-1.10), but there was an indication of publication bias in these studies.
|
16503463 |
2006 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent evidence is accumulating that some clotting factors (fibrinogen, factor VII, von Willebrand factor) and fibrinolytic factors (t-PA and PAI-1) are associated with an increased risk of coronary artery disease.
|
9519344 |
1998 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several longitudinal cohort studies of patients with manifest coronary heart disease (CHD) have linked elevated plasma PAI-1 or tPA antigen concentrations to future cardiovascular events, particularly myocardial infarction.
|
8578529 |
1995 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a sample of both 83 healthy individuals and 105 young patients with coronary artery disease from Sweden, the frequency of the 4G allele is roughly 0.5, and those individuals homozygous for the 4G allele have higher levels of PAI-1 than those with other genotypes (29% higher).
|
1456879 |
1992 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased plasma plasminogen activator inhibitor-1 (PAI-1) concentration has been identified as a risk factor for coronary heart disease.
|
9445260 |
1998 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results from these studies further suggest that individuals with this responsive 2/2 PAI-1 genotype may reflect the additional inherent potential for later HTG-VLDL- or Lp(a)-induced fibrinolytic dysfunction, resulting in the early initiation of thrombosis, atherogenesis, and coronary artery disease.
|
9409314 |
1997 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
|
10803689 |
2000 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
|
8560407 |
1995 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ApoE polymorphism may accelerate the development of coronary heart disease often seen in Caucasian patients with type 1 diabetes and diabetic nephropathy, a condition characterized by elevated plasma PAI-1 in men.
|
10809802 |
2000 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the systematic meta-analysis, the highest quantile of blood PAI-1 level was associated with higher CHD risk comparing with the lowest quantile (odds ratio=2.17; 95% CI: 1.53, 3.07) in an age- and sex-adjusted model.
|
28550093 |
2017 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss two aspects of the molecular bases of CHD: i) Molecular bases of the candidate gene related to lipoprotein metabolism including apolipoprotein AI-CIII-AIV gene duster, apolipoprotein B, apolipoprotein E-CI-CII gene cluster, apolipoprotein(a), LDL receptors, lipoprotein lipase, cholesteryl ester transfer protein, and apo B editing protein; ii) Molecular bases of the candidate gene related to thrombotic and other factors including fibrinogen, factor VII, plasminogen activator inhibitor 1, homocysteine, stromelysin, paraoxonase, and angiotensin converting enzyme.
|
9539312 |
1998 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analyses confirmed the effects of the PAI-1 gene-smoking interaction on CHD risk.
|
16424345 |
2006 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
|
10577569 |
1999 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the relationship between the 4G/5G polymorphism and plasma PAI-1 antigen levels in 104 Japanese males not taking lipid-lowering drugs and without non-insulin-dependent (type 2) diabetes mellitus or coronary artery disease.
|
10641442 |
1999 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasians.
|
10720441 |
2000 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Circulating (PAI-1) levels are elevated in patients with coronary heart disease and may play an important role in the development of atherothrombosis.
|
9198234 |
1997 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, HDL from CHD and ACS patients loses the ability of healthy HDL to suppress TF and to increase TFPI and t-PA and instead enhances PAI-1 and arterial thrombus formation.
|
25056722 |
2014 |